http://purl.org/np/RA4PzeAbzO... RA4PzeAbzO

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Vincent Emonet

2022-09-16T11:51:04.742Z

http://purl.org/np/RA4PzeAbzO... RA4PzeAbzO

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

First, we estimated the change in the percentage of prescriptions for overall antipsychotics, FGA, and SGA for anxiety disorder visits from 2005 to 2013. We calculated the annual antipsychotic prescription rates as the total number of antipsychotic prescriptions divided by the total number of eligible patients with anxiety visits. The same patients are counted several times if they have several visits.We then stratified this 9-year dataset into three equal parts (2005–2007, 2008–2010, and 2011–2013) and examined the time trends in antipsychotic treatments during anxiety visits. We transformed the calendar years by subtracting 2005 from the year and dividing the results by 8. Thus, the transformed values were 0 for 2005 and 1 for 2013. The odds ratios associated with this transformed variable represent change in the odds of visits in which antipsychotic medication was prescribed across the entire study period (2005–2013). For example, an odds ratio of 2.0 denotes twice the odds that a visit included an antipsychotic at the end (2013) as compared with the start (2005) of the study period. Adjusted odds ratios (aOR) were calculated from the multivariate logistic model with adjustment for age and sex. We repeated similar analysis to examine the trends in the use of selective FGA (i.e., flupenxiol and sulpiride) and individual SGA (i.e., clozapine, risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone). (...) First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics

Vincent Emonet

2022-09-16T11:51:04.742Z

http://purl.org/np/RA4PzeAbzO... RA4PzeAbzO

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/MONDO_0005618 MONDO_0005618

Vincent Emonet

2022-09-16T11:51:04.742Z

http://purl.org/np/RA4PzeAbzO... RA4PzeAbzO

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Vincent Emonet

2022-09-16T11:51:04.742Z

http://purl.org/np/RA4PzeAbzO... RA4PzeAbzO

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

http://identifiers.org/drugbank/DB00363 DB00363

Vincent Emonet

2022-09-16T11:51:04.742Z

http://purl.org/np/RA4PzeAbzO... RA4PzeAbzO

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/has_population_context has_population_context

http://purl.org/np/RA4PzeAbzO...#context context

Vincent Emonet

2022-09-16T11:51:04.742Z

http://purl.org/np/RA4PzeAbzO... RA4PzeAbzO

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/category category

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Vincent Emonet

2022-09-16T11:51:04.742Z

http://purl.org/np/RA4PzeAbzO... RA4PzeAbzO

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/aggregator_knowledge_source aggregator_knowledge_source

https://w3id.org/biolink/infores/knowledge-collaboratory knowledge-collaboratory

Vincent Emonet

2022-09-16T11:51:04.742Z

http://purl.org/np/RA4PzeAbzO... RA4PzeAbzO

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/publications publications

http://www.ncbi.nlm.nih.gov/pubmed/31077503 pubmed/31077503

Vincent Emonet

2022-09-16T11:51:04.742Z

http://purl.org/np/RA4PzeAbzO... RA4PzeAbzO

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

http://purl.obolibrary.org/obo/NCIT_C94303 NCIT_C94303

Vincent Emonet

2022-09-16T11:51:04.742Z